Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Neoadjuvant Chemoradiotherapy for LARC
NCT05877573Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jul 2023
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of toripalimab in rectal cancer, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Pathological Complete Response Rate at 6 months. Started Jul 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05877573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877573.